Navigation Links
Stem cells help in the understanding of drug-resistant, recurrent tumors

Massachusetts General Hospital (MGH) researchers have zeroed in on ovarian cancer stem cells that make the management of tumors all the more complex. Getting into the nuances of the stem like traits of cells will assist in developing better ways to combat ovarian cancer. //

"We feel these stem-like cancer cells may be resistant to traditional chemotherapy and could be responsible for the ultimately fatal drug-resistant recurrence that is characteristic of ovarian cancer," says Paul Szotek, MD, of the MGH Pediatric Surgical Research Laboratories, first author of the PNAS report. "We believe this likely is the first time stem-like cells have been found in models of ovarian cancer and in cells associated with human ovarian cancer."

Several recent studies have identified tiny populations of tumor cells that appear to act like stem cells, driving the tumor's ability to grow and spread. If some of these specialized cells escaped destruction by chemotherapy or radiation, the tumor would be able to recur quickly, often in a form resistant to chemotherapy. Similar cancer stem cells have been previously identified in leukemia and breast cancer and in cell lines of central nervous system and gastrointestinal tumors.

Standard treatment for ovarian cancer – surgical removal of all involved tissues followed by chemotherapy – usually appears successful, but treatment-resistant tumors recur in the vast majority of patients, leading to a five-year survival rate of less than 30 percent. Those factors and other observations suggested that cancer stem cells may also be found with ovarian tumors, leading to the current study.

The MGH researchers first examined two mouse ovarian cancer cell lines and identified cells with characteristics of the cancer stem cells found with other tumors. They then observed a small percentage of stem-like cells in human ovarian cancer lines and in cells taken from ascites fluid that had accumulated within t he abdomen of several ovarian cancer patients. When mouse ovarian tumor stem-like cells were injected under the skin of mice, they led to the formation of new tumors much faster than did injections of regular tumor cells.

Although the potential ovarian cancer stem cells were less responsive than regular tumor cells to in vitro treatment with the chemotherapy drug doxorubicin, the stem-like cells remained sensitive to repeated treatment with Mullerian Inhibiting Substance (MIS). This protein, important in the normal development of sexual organs, has been studied for its potential to treat several reproductive tumors by Patricia Donahoe, MD, director of the MGH Pediatric Surgical Research Laboratories and senior author of the PNAS study, and David MacLaughlin, PhD, associate director of the labs and a study co-author.

"We feel that non-traditional, possibly innovative approaches will be required to eradicate these stem-like cancer cells and ultimately cure ovarian cancer. With its potential to maintain the ability to inhibit the proliferation of these cells, MIS may play a role in these new therapeutic approaches," Donahoe says. "We intend to keep searching for stem-like cells in patient tumor samples and to study their responsiveness to both chemotherapeutic agents and to novel agents specifically targeted to stem cell as individualized therapy of the future." Donahoe is the Marshall K. Bartlett Professor of Surgery at Harvard Medical School.

Source :Eureka Alert


'"/>




Related medicine news :

1. Action of nerve cells
2. Therapy for stopping the spread of cancer cells
3. Hydroxyurea derivatives kill colon cancer cells
4. Creating brain cells from bone marrow
5. A Chinese herb kills cancer cells
6. Immune cells halt round in space
7. Transforming stem cells to lung cells
8. Changing stem cells to liver cells
9. Enzyme stimulates growth of adult stem cells
10. Stem cells aid to cure brain cancer
11. Brain cells protected by new compounds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions will ... 16th to 18th at the Broward County Convention Center. The event is a ... on best practices in public facility management. Intellitec Solutions will highlight their customized ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer ... inconsistencies of adding BC and AD, saying it is time to set the record ... Christ. Yisrayl says this simply cannot possibly be true and offers explanation. , “To ...
(Date:4/29/2016)... ... April 29, 2016 , ... Orthodontics Limited, one ... Dr. Gemmi and Dr. Middleberg, were asked by Invisalign to present ... During the seminar, titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. Gemmi ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... California Dental Association, today announced it has signed a letter of intent with ... (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 years ...
(Date:4/28/2016)... , ... April 28, 2016 , ... La Sirena Foods ... one in Central America and is looking to grow their market share in the ... an exceptional brand as La Sirena Foods and indirectly with Otis ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology: